Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.
about
Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysisProstate cancer epigenetics and its clinical implicationsEvolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerBudget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending.Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detectionExpression changes in the stroma of prostate cancer predict subsequent relapseImaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical OverviewMethylation of the RARB gene increases prostate cancer risk in black AmericansRHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer.In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: Prostatic intraepithelial neoplasia.Risk stratification in prostate cancer screening.APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation.Histopathological screening for prostate carcinoma: is a benign biopsy a negative biopsy?Biomarkers in prostate cancer: new era and prospective.Prognostic DNA methylation markers for prostate cancer.Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?Commercialized biomarkers: new horizons in prostate cancer diagnostics.Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.Clinical Utility of Biomarkers in Localized Prostate Cancer.Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levelsMinimally invasive prostate cancer detection test using FISH probes.Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients.Tissue-based biomarkers in prostate cancer.Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.[Molecular biomarkers and prognostic factors for prostate cancer].Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
P2860
Q28533760-45CA3C66-39CF-4EE5-8757-FEDBD0587727Q28829460-FAE00C07-F1AD-4162-AE4A-129C402513B5Q30938412-9934FBF2-26DF-41C0-B7EC-19EEF9FFE1B4Q33652793-55D4FE37-8B69-495D-94BF-544099E3EB6EQ33805477-0C3B89E4-7B86-4046-9954-28FF9E01147FQ34294196-8056574E-A4A9-43F2-B8C2-527CF88E8022Q34368873-D20E9F61-FEC2-40F7-A47E-FFB18D9B3777Q36979944-F1BB5E16-B487-4A3F-8D1E-817B35B43E42Q37187963-7DE22D87-D2D4-44D7-A910-734BABC443F2Q37701479-21CAB08C-97E6-4F2C-854D-4BB541FE3851Q37720392-43052EFE-5FF9-43FA-AB45-7E25D63BD160Q37998079-35EE69D5-6DE6-4D8C-A53A-962958E16064Q38068114-A90F1FE3-F0AF-4874-B251-209F4814E60EQ38072660-8907ADF7-21C9-4C8C-939F-DBF144314DF1Q38194173-B9B2C5E2-19EA-48D9-BA8D-617926772110Q38232146-DFE2A492-06EE-42CE-A443-3CD437A007DFQ38232466-56FC9BC6-E97A-49B0-B245-5B1218114275Q38252624-E9B314C8-BC18-468B-AFA3-E1719C00378DQ38356863-CE0DD68E-71AC-418E-A1D0-02AA488A7777Q38364797-83E0B6E5-CAF2-46F3-9FE2-8DB1316236E3Q38392009-97BAD3ED-6D08-4119-9DDC-883F61F814EDQ38461592-0C4C2585-B4A5-4137-8FC4-93C09095BD25Q38792354-AD0D4C03-8CCE-4108-99CD-F12E521795D7Q38904571-6E02E793-26FC-4832-A778-7F2418AB3AC5Q40399854-C7D53BB6-B056-4B56-8C94-26DD3A5027E7Q41660235-18E427CD-D0F3-42C5-AA38-F859623BD9A8Q42256326-0C5F09B3-54B6-4326-B06C-FD4FF631991DQ42558314-322E7929-DC45-41BA-8EDD-BA0AD2A29DA7Q43083508-0C675AC0-D839-401B-839C-DB35A52641D9Q47144748-86FF9234-5D3C-401F-8E71-72FA12ADBA2DQ47215343-A23E472C-70A7-4FE1-BD17-7D947CFD1FF8Q49710514-F9FDFF3A-D53C-418C-B2A5-AF457DBBA44EQ53251387-5C21E5F1-B550-4374-AF8A-0F8FF2FC3526Q54529907-35F79AF3-57EE-4B31-A68A-BF9765D2CD58
P2860
Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluation of GSTP1 and APC me ...... ive initial prostate biopsies.
@ast
Evaluation of GSTP1 and APC me ...... ive initial prostate biopsies.
@en
type
label
Evaluation of GSTP1 and APC me ...... ive initial prostate biopsies.
@ast
Evaluation of GSTP1 and APC me ...... ive initial prostate biopsies.
@en
prefLabel
Evaluation of GSTP1 and APC me ...... ive initial prostate biopsies.
@ast
Evaluation of GSTP1 and APC me ...... ive initial prostate biopsies.
@en
P2093
P2860
P1433
P1476
Evaluation of GSTP1 and APC me ...... ive initial prostate biopsies.
@en
P2093
Bhargavi Raghavan
Bruce J Trock
David McLeod
Eric A Klein
J Stephen Jones
Jonathan I Epstein
Joseph W Bigley
Jyoti Mehrotra
Leslie A Mangold
Michelle J Brotzman
P2860
P356
10.1111/J.1464-410X.2011.10718.X
P577
2011-11-11T00:00:00Z